Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Northwestern University Feinberg School of Medicine, Chicago, IL, United States



Survival: 17.4 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Chicago, IL
   
Hospital: Northwestern University Feinberg School of Medicine
   
Journal: Link
   
Date: 1/2013

Description:
Patients:
This phase 2 study involved female HER2-negative advanced breast cancer patients who were divided into two separate treatment groups. Group A had 119 patients with an average age of 50.6 years. Group B had 118 patients with a median age of 53.1 years.

Treatment:
Patients in group A were treated with the chemotherapy agent paclitaxel and the biologic therapy agent sorafenib, which is a multikinase inhibitor that interferes with cancer cell growth.

Patients in group B were treated with paclitaxel and a placebo.

Toxicities:
Adverse event-related deaths were reported in group A; causes included malaria, liver dysfunction, and heart attack. Grade 4 neutropenia, mucosal inflammation, and shortness of breath were also reported.

There were three adverse event-related deaths in group B due to meningitis and an unknown cause. Grade 4 neutropenia and grade 3 nerve toxicities were also reported.

Results:
The median overall survival for group A and B was 16.8 and 17.4 months, respectively.

Support:
This study was partially supported by Onyx Pharmaceuticals and Bayer Healthcare Pharmaceuticals.

Correspondence: Dr. William J. Gradishar; email: w-gradishar@northwestern.edu

E-mail to a Friend Email Physician More Information